Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.

Détails

ID Serval
serval:BIB_40DFB820173A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.
Périodique
Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer
Auteur(s)
Gautschi O., Milia J., Cabarrou B., Bluthgen M.V., Besse B., Smit E.F., Wolf J., Peters S., Früh M., Koeberle D., Oulkhouir Y., Schuler M., Curioni-Fontecedro A., Huret B., Kerjouan M., Michels S., Pall G., Rothschild S., Schmid-Bindert G., Scheffler M., Veillon R., Wannesson L., Diebold J., Zalcman G., Filleron T., Mazières J.
ISSN
1556-1380 (Electronic)
ISSN-L
1556-0864
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
10
Numéro
10
Pages
1451-1457
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study
Publication Status: ppublish
Résumé
INTRODUCTION: Approximately 2% of lung adenocarcinomas have BRAF (v-Raf murine sarcoma viral oncogene homolog B) mutations, including V600E and other types. Vemurafenib, dabrafenib, and sorafenib as BRAF inhibitors are currently tested in clinical trials, but access for patients is limited. The aim of this study was to document the clinical course of patients treated outside of clinical trials.
METHODS: We conducted a retrospective multicenter cohort study in Europe of patients with advanced BRAF-mutant lung cancer treated with known BRAF inhibitors. Data were anonymized and centrally assessed for age, gender, smoking, histology, stage, local molecular diagnostic results, systemic therapies, and survival. Best response was assessed locally by RECIST1.1.
RESULTS: We documented 35 patients treated in 17 centers with vemurafenib, dabrafenib, or sorafenib. Median age was 63 years (range 42-85); gender was balanced; 14 (40%) were never smokers; all (100%) had adenocarcinoma; 29 (83%) had V600E; 6 (17%) had other mutations; one of them had a concomitant KRAS mutation. Thirty (86%) patients had chemotherapy in the first line. Overall survival with first-line therapy was 25.3 months for V600E and 11.8 months for non-V600E. Thirty-one patients received one BRAF inhibitor, and four received a second inhibitor. Overall response rate with BRAF therapy was 53%, and disease control rate was 85%. Median progression-free survival with BRAF therapy was 5.0 months, and overall survival was 10.8 months.
CONCLUSIONS: These results confirm the activity of targeted therapy in patients with BRAF-mutant lung adenocarcinoma. Further trials are warranted to study combination therapies and drug resistance mechanisms.
Mots-clé
Adult, Aged, Aged, 80 and over, Cohort Studies, Female, Humans, Lung Neoplasms/drug therapy, Lung Neoplasms/enzymology, Male, Middle Aged, Molecular Targeted Therapy, Protein Kinase Inhibitors/therapeutic use, Proto-Oncogene Proteins B-raf/antagonists & inhibitors, Proto-Oncogene Proteins B-raf/genetics, Retrospective Studies
Pubmed
Web of science
Open Access
Oui
Création de la notice
19/10/2015 13:36
Dernière modification de la notice
08/05/2019 17:38
Données d'usage